抗吸收相关性颌骨坏死的风险因素及预防的回顾与更新。
Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw.
机构信息
Division of Endocrinology and Metabolism, Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea.
出版信息
Endocrinol Metab (Seoul). 2021 Oct;36(5):917-927. doi: 10.3803/EnM.2021.1170. Epub 2021 Oct 21.
Abstract
Antiresorptive-related osteonecrosis of the jaw (ARONJ) is a rare but serious adverse event of bisphosphonate or denosumab administration; it is associated with severe pain and a deteriorated quality of life. Since its first report in 2003, there have been many studies on its definition, epidemiology, pathophysiology, diagnosis, and treatment. Nevertheless, the epidemiology and mechanisms underlying this condition have not yet been fully delineated and several risk factors are known. Moreover, as there is no effective treatment currently available for osteonecrosis of the jaw, prevention is essential. Furthermore, close cooperation between prescribing physicians and dentists is important. The aim of this review was to provide up-to-date information regarding the risk factors and prevention of ARONJ from a physician's perspective.
摘要
抗吸收性颌骨坏死（ARONJ）是双膦酸盐或地舒单抗治疗的一种罕见但严重的不良反应；它与严重疼痛和生活质量恶化有关。自 2003 年首次报告以来，已经有许多关于其定义、流行病学、病理生理学、诊断和治疗的研究。然而，这种情况的流行病学和机制尚未完全阐明，已知有几个危险因素。此外，由于目前尚无有效的颌骨坏死治疗方法，预防至关重要。此外，处方医生和牙医之间的密切合作也很重要。本综述的目的是从医生的角度提供有关 ARONJ 的危险因素和预防的最新信息。
相似文献
1
Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw.
Endocrinol Metab (Seoul). 2021 Oct;36(5):917-927. doi: 10.3803/EnM.2021.1170. Epub 2021 Oct 21.
2
Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
Tohoku J Exp Med. 2019 Feb;247(2):75-86. doi: 10.1620/tjem.247.75.
3
Update MRONJ and perspectives of its treatment.
J Stomatol Oral Maxillofac Surg. 2017 Sep;118(4):232-235. doi: 10.1016/j.jormas.2017.06.012. Epub 2017 Jul 8.
4
Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
Dent Update. 2015 Jun;42(5):436-8, 440. doi: 10.12968/denu.2015.42.5.436.
5
CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Dentomaxillofac Radiol. 2018 May;47(4):20170323. doi: 10.1259/dmfr.20170323. Epub 2018 Feb 13.
6
[Current situation and future issues of antiresorptive agent-related osteonecrosis of the jaw].
Nihon Yakurigaku Zasshi. 2019;153(1):22-27. doi: 10.1254/fpj.153.22.
7
Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.
Odontology. 2018 Oct;106(4):469-480. doi: 10.1007/s10266-018-0362-5. Epub 2018 Apr 30.
8
Drug-induced osteonecrosis of the jaw: the state of the art.
Reumatismo. 2017 May 22;69(1):9-15. doi: 10.4081/reumatismo.2017.983.
9
The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):509-16. doi: 10.1016/j.coms.2015.06.003. Epub 2015 Sep 9.
10
Treatment of Medication-Related Osteonecrosis of the Jaw: Controversies in Causality and Therapy.
Dent Clin North Am. 2024 Jan;68(1):67-85. doi: 10.1016/j.cden.2023.07.005. Epub 2023 Aug 30.
引用本文的文献
1
What is the appropriate antibiotic administration to prevent MRONJ development after tooth extraction?
J Bone Miner Metab. 2025 Jul 2. doi: 10.1007/s00774-025-01617-8.
2
Prevalence of MRONJ in patients treated with antiresorptive agents for glucocorticoid-induced osteoporosis.
Oral Maxillofac Surg. 2025 Apr 16;29(1):84. doi: 10.1007/s10006-025-01383-x.
3
A Systematic Review of Laser Photobiomodulation Dosimetry and Treatment Protocols in the Management of Medications-Related Osteonecrosis of the Jaws: A Rationalised Consensus for Future Randomised Controlled Clinical Trials.
Pharmaceuticals (Basel). 2024 Jul 31;17(8):1011. doi: 10.3390/ph17081011.
4
Polysacharide of Agaricus blazei gel mitigates bone necrosis in model of the jaws related to bisphosphonate via Wnt signaling.
Sci Rep. 2024 Apr 8;14(1):8215. doi: 10.1038/s41598-024-58445-5.
5
Editorial: Immunological processes in maxillofacial bone pathology.
Front Immunol. 2024 Mar 13;15:1394835. doi: 10.3389/fimmu.2024.1394835. eCollection 2024.
6
Risk factors for dental findings of the development of medication-related osteonecrosis of the jaw: Investigation of 3734 teeth in cancer patients receiving high dose antiresorptive agents.
J Dent Sci. 2024 Jan;19(1):203-210. doi: 10.1016/j.jds.2023.04.026. Epub 2023 May 10.
7
Dental Management of Medication-Related OSTEONECROSIS of the JAW: WHILE RARE, THIS PATHOLOGY HAS DEVASTATING EFFECTS ON PATIENT HEALTH AND QUALITY OF LIFE.
Decis Dent. 2023 Sep;9(8):28-31. Epub 2023 Sep 11.
8
Correlations between Immune Response and Etiopathogenic Factors of Medication-Related Osteonecrosis of the Jaw in Cancer Patients Treated with Zoledronic Acid.
Int J Mol Sci. 2023 Sep 20;24(18):14345. doi: 10.3390/ijms241814345.
9
Clinical and Histopathological Aspects of MRONJ in Cancer Patients.
J Clin Med. 2023 May 10;12(10):3383. doi: 10.3390/jcm12103383.
10
Safety and Efficacy of Pamidronate in Neonatal Hypercalcemia Caused by Subcutaneous Fat Necrosis: A Case Report.
Front Pediatr. 2022 Apr 28;10:845424. doi: 10.3389/fped.2022.845424. eCollection 2022.
本文引用的文献
1
Is implant surgery a risk factor for osteonecrosis of the jaw in older adult patients with osteoporosis? A national cohort propensity score-matched study.
Clin Oral Implants Res. 2021 Apr;32(4):437-447. doi: 10.1111/clr.13713. Epub 2021 Jan 26.
2
Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study.
Bone. 2021 Feb;143:115650. doi: 10.1016/j.bone.2020.115650. Epub 2020 Sep 19.
3
Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020.
Int J Environ Res Public Health. 2020 Aug 18;17(16):5998. doi: 10.3390/ijerph17165998.
4
Therapeutic approach and management algorithms in medication-related osteonecrosis of the jaw (MONJ): recommendations of a multidisciplinary group of experts.
Arch Osteoporos. 2020 Jul 4;15(1):101. doi: 10.1007/s11657-020-00761-0.
5
Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review.
Heliyon. 2020 Apr 27;6(4):e03795. doi: 10.1016/j.heliyon.2020.e03795. eCollection 2020 Apr.
6
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline.
J Clin Oncol. 2019 Sep 1;37(25):2270-2290. doi: 10.1200/JCO.19.01186. Epub 2019 Jul 22.
7
Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database.
Ther Clin Risk Manag. 2018 Dec 24;15:59-64. doi: 10.2147/TCRM.S176620. eCollection 2019.
8
Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review.
Bone. 2019 Apr;121:60-67. doi: 10.1016/j.bone.2019.01.003. Epub 2019 Jan 4.
9
Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2019 Feb;127(2):117-135. doi: 10.1016/j.oooo.2018.09.008. Epub 2018 Oct 9.
10
The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention.
Biomed Res Int. 2018 Sep 16;2018:2684924. doi: 10.1155/2018/2684924. eCollection 2018.
Zotero 插件